Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotic LP-LDL® shows promise for diabetes and prediabetes management

NCT ID NCT07373392

First seen Jan 28, 2026 · Last updated Jun 12, 2026 · Updated 19 times

Summary

This study tests whether a daily probiotic called LP-LDL® can improve cholesterol, blood sugar, inflammation, and memory in 210 adults with prediabetes, type 1, or type 2 diabetes who also have high cholesterol or triglycerides. Participants take either the probiotic or a placebo for 12 weeks, followed by a 4-week break. The goal is to see if this supplement can help manage disease and reduce related health risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Health Science and Technology, Aalborg University

    Gistrup, 9260, Denmark

  • Steno Diabetes Center Nordjylland

    Gistrup, 9260, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia Insulin Resistance prediabetes syndrome type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.